This articles has been corrected to clarify that AltheaDx will offer the DxS assay as a service and not as a distributor.
 
NEW YORK (GenomeWeb News) – AltheaDx will offer as a service DxS’ genetic assay for K-RAS mutations for use in clinical studies in the US, Manchester, UK-based DxS said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.